Mayinglong Pharmaceutical Group Co Ltd (SHG:600993) — Market Cap & Net Worth
Market Cap & Net Worth: Mayinglong Pharmaceutical Group Co Ltd (600993)
Mayinglong Pharmaceutical Group Co Ltd (SHG:600993) has a market capitalization of $1.63 Billion (CN¥11.12 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #7083 globally and #1668 in its home market, demonstrating a 2.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mayinglong Pharmaceutical Group Co Ltd's stock price CN¥25.80 by its total outstanding shares 431053891 (431.05 Million). Analyse cash flow conversion of Mayinglong Pharmaceutical Group Co Ltd to see how efficiently the company converts income to cash.
Mayinglong Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Mayinglong Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.27 Billion to $1.63 Billion (3.05% CAGR).
Mayinglong Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mayinglong Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.44x
Mayinglong Pharmaceutical Group Co Ltd's market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.12x
Mayinglong Pharmaceutical Group Co Ltd's market cap is 3.12 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.27 Billion | $1.78 Billion | $223.26 Million | 0.71x | 5.67x |
| 2016 | $1.16 Billion | $2.10 Billion | $250.24 Million | 0.55x | 4.63x |
| 2017 | $1.20 Billion | $1.75 Billion | $320.05 Million | 0.68x | 3.75x |
| 2018 | $797.62 Million | $2.20 Billion | $176.21 Million | 0.36x | 4.53x |
| 2019 | $1.05 Billion | $2.71 Billion | $359.97 Million | 0.39x | 2.91x |
| 2020 | $1.22 Billion | $2.79 Billion | $419.06 Million | 0.44x | 2.91x |
| 2021 | $1.76 Billion | $3.39 Billion | $464.59 Million | 0.52x | 3.79x |
| 2022 | $1.41 Billion | $3.53 Billion | $478.57 Million | 0.40x | 2.94x |
| 2023 | $1.53 Billion | $3.14 Billion | $443.25 Million | 0.49x | 3.44x |
| 2024 | $1.65 Billion | $3.73 Billion | $528.09 Million | 0.44x | 3.12x |
Competitor Companies of 600993 by Market Capitalization
Companies near Mayinglong Pharmaceutical Group Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Mayinglong Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Mayinglong Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Mayinglong Pharmaceutical Group Co Ltd's market cap moved from $1.27 Billion to $ 1.63 Billion, with a yearly change of 3.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.63 Billion | -7.86% |
| 2025 | CN¥1.77 Billion | +7.24% |
| 2024 | CN¥1.65 Billion | +7.98% |
| 2023 | CN¥1.53 Billion | +8.45% |
| 2022 | CN¥1.41 Billion | -20.17% |
| 2021 | CN¥1.76 Billion | +44.29% |
| 2020 | CN¥1.22 Billion | +16.44% |
| 2019 | CN¥1.05 Billion | +31.45% |
| 2018 | CN¥797.62 Million | -33.48% |
| 2017 | CN¥1.20 Billion | +3.55% |
| 2016 | CN¥1.16 Billion | -8.51% |
| 2015 | CN¥1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Mayinglong Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.63 Billion USD |
| MoneyControl | $1.63 Billion USD |
| MarketWatch | $1.63 Billion USD |
| marketcap.company | $1.63 Billion USD |
| Reuters | $1.63 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more